The Botox for Myofascial Pain Syndrome is typically characterized by the presence of trigger points that are subject to treatment through the injections of small doses of the Botulinum toxin type A (BTX-A). These produce prolonged muscle relaxation and can be easily targeted at the affected muscles.
A vast number of research reports advocate the use of BTX-A injections in the treatment of the Myofascial Pain Syndrome and Fibromyalgia.
A study was conducted by the Pain Evaluation & Treatment Centre in Tulsa for the purpose. 70 percent of patients with MPS in the back and extremities who received the BTX-A injections over a two year period reported a remarkable pain relief for 2.5 to 3.6 months. The patients were even able to support a therapeutic exercise regimen along with.